INTRODUCTION
The interaction between tumor cells and host immune cells plays an important role in multiple stages of tumorigenesis, and recent clinical evidence suggests a potential contribution of host immune responses in modulating the clinical outcome of cancer patients. 1, 2 Moreover, manipulation of the endogenous immune system has emerged as an effective anticancer therapy in patients with advanced cancer. 3, 4 Interestingly, accumulating evidence has revealed that the tumor microenvironment has a significant impact on the functional properties of certain immunoregulatory components that regulate whether host responses promote or antagonize tumor growth. Tumor cells and tumor-infiltrating lymphocytes adopt strategies to evade antitumor processes and may enhance the metastatic potential through the activation of chronic inflammatory signals. 5, 6 Together, these observations underscore the complexity of host immune system regulatory pathways in the regulation of tumorigenesis.
In this article, we describe the potential impact of the T-cell immunoglobulin mucin (TIM) gene family in tumor immunosurveillance and immunoevasion and the impact of different tumor microenvironments on the therapeutic responses of TIM-targeted therapies.
MECHANISMS OF TUMOR IMMUNOSURVEILLANCE AND IMMUNOEVASION
Transformation is established by overcoming multiple intrinsic and extrinsic tumor suppression mechanisms. Transformed cells are detected intrinsically using checkpoint mechanisms that survey genetic and epigenetic abnormalities such as oncogene-induced senescence, DNA damage responses or apoptotic/necrotic cell death programs. 7 Extrinsic tumor surveillance systems detect transformed cells by utilizing non-transformed cells within tumor microenvironments. In particular, the innate and adaptive immune systems play a critical role in detecting and eliminating transformed cells by activating multiple sets of myeloid cells and lymphocytes. 2 Interestingly, tumor-infiltrating immune cells also contribute to tumor progression by triggering tumor angiogenesis and immune suppression. [8] [9] [10] These findings suggest that the host immune system contributes to tumor initiation and progression in a contradictory manner.
Although the mechanisms that regulate tumor immune responses require further clarification, the recent concept of 'cancer immunoediting' might explain the differential temporal and spatial dynamism of tumor immunosurveillance and immunoevasion, as evidenced by the antitumorigenic and protumorigenic host immune responses during different phases of tumorigenesis. Classically, cancer immunoediting has been divided into three phases: elimination, equilibrium and escape. In the elimination phase, innate and adaptive lymphocytes detect the presence of transformed cells and remove them. However, tumor immunosurveillance selectively eliminates highly immunogenic transformed cells, while poorly immunogenic cells survive and enter into the equilibrium phase. The interaction between surviving tumor variants and immune cells creates a homeostasis in which low-level malignant and/ or quiescent tumor cells coexist with lymphocytes. After a longterm equilibrium between tumor cells and lymphocytes, additional genetic and epigenetic alterations allow tumor cells to evade tumor immunosurveillance. During this immunoevasion phase, tumor cells not only circumvent antitumor immunity, but also promote tumorigenic activities through multiple tumor-intrinsic and extrinsic machineries. 8, 10, 11 These immunoevasion mechanisms elicited by the tumor microenvironment include the secretion of immunosuppressive cytokines, the emergence of tumor antigen-loss variants and the subversion of antigen-specific CTL responses by immunosuppressive antigen-presenting cells (APCs). [12] [13] [14] [15] [16] Moreover, the tumor microenvironment adopts multiple strategies to subvert tumor immunosurveillance by recruiting immunosuppressive myeloid cells, such as IDO 1 dendritic cells (DCs), B7-1 1 macrophages, angiogenic DCs and Foxp3 1 regulatory T cells (Tregs), which severely compromise endogenous immunogenicity and impair therapeutic responses to immunotherapy. [17] [18] [19] More importantly, tumor cells exploit host immunity to create intimal networks among tumor cells, stromal cells and endothelial cells and to promote pro-tumorigenic inflammation-associated carcinogenic responses such as angiogenesis and epithelial-mesenchymal transitions. 20, 21 Tumor immunoevasion has multiple impacts on tumorigenesis by triggering tolerogenic responses to tumor cells and by exploiting pro-tumor inflammation.
THE ROLE OF TIM MOLECULES IN THE REGULATION OF IMMUNE HOMEOSTASIS
TIM proteins are type-I cell-surface glycoproteins composed of a signal peptide, an extracellular IgV domain, a mucin-like domain, a transmembrane domain, and an intracellular cytoplasmic tail. All members share a conserved sequence homology in the IgV domains, while other domains demonstrate poor homology (Figure 1 ). Under healthy conditions, the TIM family is largely confined to restricted sets of lymphoid and myeloid lineage cells and kidney epithelial cells. However, the induction of TIM gene family members is frequently observed on cell types such as stromal cells, endothelial cells and transformed cells in chronic viral infections and cancer, implying that TIM proteins play a critical role in the regulation of these pathological conditions. 22, 23 Moreover, the TIM gene family has multiple roles in the regulation of immune activation and tolerance, which may have a large impact on the clinical consequences of sterile inflammation, antimicrobial defense and antitumor immune responses. 24, 25 For example, continuous blockade of TIM-3 causes autoimmune nephritis in immune competent animals, and TIM-3 triggers antimicrobial immunity by interacting with galectin-9 26 and impedes innate antitumor responses. 27, 28 Moreover, TIM-1 promotes pro-inflammatory responses that may be associated with aggressive graft-versus-host disease. 29 Thus, these findings raise the possibility that TIM family members serve as critical checkpoints to regulate immune homeostasis and inflammation. More importantly, accumulating evidence has unveiled the critical roles of TIM family members in the regulation of antitumor immunosurveillance. Thus, we will provide an overview of TIM-mediated regulation of tumor immunity and perspectives on the potential of TIM family members for tumor immunosurveillance and immunoevasion.
THE ROLE OF TIM MOLECULES IN THE IMMUNE REGULATION OF TUMORS
TIM-1 TIM-1 is mainly expressed on T cells and kidney epithelial cells. 24, 25 Several lines of evidence suggest a dual role for TIM-1 in the regulation of T cell-mediated immunity. TIM-1 may act as a costimulatory molecule for T-cell activation 30, 31 or transduce a negative signal that leads to the inhibition of T-cell effector function. 32 Several studies have reported multiple roles for TIM-1 in creating immunostimulatory or immunosuppressive environments. For example, treatment with anti-TIM-1 antibodies in the effector phase impedes the development of inflammation, while treatment during the priming phase results in a break in immune tolerance. [31] [32] [33] In addition, TIM-1 on the surface of macrophages acts as a phosphatidylserine receptor that phagocytoses apoptotic cells. 34 Thus, it is highly likely that TIM-1 play a role in the efficient clearance of apoptotic cells and the maintenance of tumor microenvironment homeostasis.
The molecular mechanism of TIM-1-mediated immune regulation has been recently demonstrated. In this study, TIM-1 recycles from the cell surface to endosomes using clathrin-dependent endocytosis pathways, and it suppresses the expression of the orphan nuclear receptor NUR77 through lysosomal degradation pathways, thus protecting kidney epithelial cells from NUR77-mediated apoptotic death signals.
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NUR77 also serves as a lineage-specific factor that promotes monocyte differentiation from BM precursors. 36 Additionally, NUR77 inhibits pro-inflammatory activities by myeloid cells in murine atherosclerosis models. 37 Thus, NUR77 may contribute to the creation of tolerogenic microenvironments by generating immunosuppressive myeloid cell lineages. It is tempting to speculate that TIM-1 generates tolerogenic myeloid cells that promote pro-inflammatory responses by interfering with NUR77-dependent immunosuppressive programs ( Figure 2 ).
TIM-1 has multiple functions in the regulation of tolerance and immunity depending on the cell type and microenvironment; it remains unclear whether the functional multiplicity of TIM-1 could affect the direction and quality of antitumor immunity and tumor-associated inflammation (Figure 3 ). Figure 1 The structure and main domains of TIM gene family members. The sequences (a) and schematic structures (b) are shown for each TIM gene family member. TIM molecules are type-I cell-surface glycoproteins that comprise an extracellular IgV domain, a mucin-like domain, a transmembrane domain and an intracellular cytoplasmic tail. All TIM molecules have a conserved sequence homology in the IgV domains, while other domains show little similarity. The sequence data were generated using the PRALINE multiple sequence alignment function. TIM, T-cell immunoglobulin mucin. and the production of Th2 cytokines such as IL-4 and IL-10, thus demonstrating a critical role for TIM-2 in the regulation of Th2-mediated immunity. 38, 39 TIM-2 has also been identified as a potential ligand for the semaphorin family member Semaphorin 4A (Sema4A). 40 Sema4A is expressed on antigen presenting cells such as dendritic cells and activated B cells, and it plays an important role in supporting the effector function and survival of Tregs. 41 Because Tregs are a major population that inhibit intratumoral effector responses and tumor infiltration of Treg may be associated with poor prognosis in cancer patients, 42 the interaction between TIM-2 and Sema4A may act as a barrier against efficient antitumor immunity by activating Treg-dependent mechanisms (Figure 2 ). The relevance of TIM-2-mediated regulation in Th2 and/or Treg function remains largely unknown. However, it is plausible that TIM-2 may contribute to an immunosuppressive environment that favors tumor cell survival at early stages of immunosurveillance; TIM-2 might additionally have a dual role in inflammation-driven tumorigenesis by regulating protumorigenic Th2 and anti-inflammatory Treg responses 43, 44 ( Figure 3 ).
TIM-3
TIM-3 negatively regulates Th1 cell responses by binding with galectin-9, and under normal conditions, TIM-3-mediated immune regulation is fine-tuned through negative regulation by HLA-B-associated transcript-3. 45, 46 Consistent with its immunoregulatory actions, several studies have revealed that the interaction between TIM-3 and galectin-9 causes exhaustion and apoptosis of antigen-specific CTLs in chronic viral infection and cancer. [47] [48] [49] It has been demonstrated that the TIM-3/galectin-9 pathway is responsible for repressing intratumoral immune responses in patients with hepatitis B virus-associated hepatocellular carcinomas. 50 Moreover, the exhaustion phenotype characterized by the coexpression of TIM-3 and programmed death 1 (PD-1) is frequently detected on CD8
1 T cells in tumor-bearing hosts and correlates with impaired antitumor immune responses in murine acute myelogenous leukemia models and in melanoma patients. 51, 52 TIM-3 expression has also been identified on Foxp3
1 Tregs, although the functional relevance of this population compared to other subsets should be explored in future studies. 53 In addition, recent studies have revealed that TIM-3 regulates innate immune responses. The upregulation of TIM-3 on DC in the tumor microenvironment negatively regulates innate responses to nucleic acids released from apoptotic tumor cells through its interaction with HMGB1. The interaction between TIM-3 and HMGB1 interferes with the endocytosis of nucleic 34 TIM-1 is also expressed on kidney epithelial cells and promotes cell survival through the degradation of nuclear factor NUR77. 35 (b) TIM-2 promotes the differentiation of Th2 cells and regulates T-cell survival and activation upon interaction with Sema4A on myeloid cells. 38, 40 (c) TIM-3 on DC suppresses innate immune signals mediated by nucleic acids or DAMPs, 27,28 whereas TIM-3 expressing T cells display exhausted phenotypes and trigger apoptosis by interacting with galectin-9. 46 TIM-3 also regulates NK cell differentiation and function. 55 (d) TIM-4 expression is largely restricted to APCs, and it serves as a phosphatidylserine receptor that regulates the engulfment of apoptotic cells; it interacts with TIM-1 on T cells to regulate the differentiation of Th1 and Th17 cells. 34, 57, 59 APC, antigen-presenting cell; DAMP, damage-associated molecular pattern; DC, dendritic cell; NK, natural killer; Sema4A, Semaphorin 4A; TIM, T-cell immunoglobulin mucin. acids into DC endosomes, which blocks innate immune signaling pathways upstream of PRR-sensing systems. 27, 28, 54 Moreover, TIM-3 expression has been demonstrated on a specific subset of natural killer cells, which might regulate cytokine profiles and cytotoxic activities by distinct mechanisms 55 ( Figure 2 ). TIM-3 serves as a negative regulator of both innate and adaptive immunity in the tumor microenvironment. We hypothesize that in an early phase of cancer immunoediting, TIM-3 could reduce antitumor immunosurveillance through coordinated and distinct suppressive actions on innate and adaptive antitumor immune responses. However, TIM-3 might dampen protumorigenic inflammation by negatively regulating inflammation in the tumor microenvironment. Moreover, TIM-3-mediated suppression of innate immune signals in inflammation-associated tumor microenvironments may modulate the tumorigenic activities of myeloid cells and attenuate tumor progression, metastasis and resistance to anticancer therapies 56 ( Figure 3) . Although further studies are needed to clarify the role of TIM-3 during immunoediting, our hypothesis further highlights the complex features of immunoregulatory molecules in the regulation of cancer immunosurveillance and immune subversion.
TIM-4
TIM-4 is another member of the TIM family that mainly functions as a phosphatidylserine receptor to enhance the engulfment of apoptotic cells. 34, 57 In contrast to TIM-3, which is expressed on multiple immune and non-immune cells, TIM-4 expression is restricted to APCs such as DCs and macrophages. 58 Recent analysis of TIM-4-deficient mice has shown that TIM-4 dampens inflammatory responses and maintains immune tolerance, implying that TIM-4 may have a potential role in the regulation of immune responses in the tumor microenvironment 59, 60 ( Figure 2 ). The role of TIM-4 in tumor immunosurveillance, and in particular the regulation of antitumor immune responses and inflammation-associated carcinogenesis, remains obscure. It is tempting to speculate that TIM-4 plays an important role in controlling tumor-specific responses by regulating the processing and presentation of antigens from phagocytosed apoptotic tumor cells. Consistent with this hypothesis, phagocytic systems for apoptotic cells such as MFG-E8/integrin-avb3 and Gas-6/TAM (Mer/Axn/tyro-3) create an immunosuppressive milieu that contributes to the maintenance of immune homeostasis and impaired tumor immunosurveillance. 61, 62 Consistent with this hypothesis, we recently found that vaccination with irradiated B16 melanoma cells expressing Thus, TIM-4 suppresses antigen-specific responses by repressing the presentation of immunogenic tumor-associated antigens and by establishing tolerized tumor environments. In contrast, tumor-associated APCs may utilize TIM-4 to counteract tumorigenic inflammation through apoptotic cell phagocytosis and the induction of immunosuppressive lymphocytes. Consistent with this idea, the presence of dying tumors due to impaired phagocytic systems provides potential sources for sterile inflammation and immune responses, which should create favorable circumstances for inflammation-driven tumorigenesis. 21, 64 Thus, depending on the inflammatory milieu within the tumor microenvironment, it is critical to evaluate whether TIM-4-mediated immune regulation is beneficial or detrimental (Figure 3 ).
THERAPEUTIC POTENTIAL OF TARGETING TIM MOLECULES AGAINST TUMORS
Accumulating evidence has demonstrated the therapeutic potential of targeting TIM-3 to activate the antitumor immune responses of T cells infiltrating human tumors. For example, combined blockade of TIM-3 and PD-1 reversed the exhaustion phenotype and enhanced tumor antigen-specific CTL activities. 65 Moreover, recent studies unveiled the therapeutic potential of targeting TIM-3 and TIM-4 in preclinical murine tumor models. For example, treatment with anti-TIM-3 monoclonal antibody (mAb) alone or in combination with immunotherapy or chemotherapy augmented antitumor responses against established subcutaneous tumor models. 51, 53, 66 In addition, treatment with anti-TIM-4 mAb augmented antitumor responses against B16 melanoma models. 63 More importantly, combined treatment with anti-TIM-3 and anti-TIM-4 mAb further maximized the efficacy of cancer vaccines by increasing the numbers and effector functions of tumorinfiltrating natural killer and CD8
1 T cells compared to either mAb alone. 63 Taken together, this experimental evidence has supported the therapeutic potential of targeting TIM-3 and TIM-4 to stimulate antitumor immune responses and improve the clinical responses of conventional anticancer regimens. Interestingly, a recent study suggested that an siRNA that disrupted the interaction between TIM-4 on DCs and TIM-1 on T cells by targeting the FG-CC9 loop enhanced the therapeutic efficacy of DC vaccines against gastric cancer; this demonstrated that the FG-CC9 loop in TIM-1/4 may be a suitable target to develop novel immunotherapeutics. 67 In contrast, anticancer strategies to suppress TIM-3 and TIM-4 activities might be detrimental in controlling tumorigenesis during sterile inflammation; further sterile inflammation caused by the blockade of TIM-3 and/or TIM-4 might accelerate protumorigenic inflammation. In the condition above, pharmacological inhibition of TIM-1 and TIM-2 in T cells might be useful for attenuating tumor progression by targeting protumorigenic inflammation and suppressing tumorigenic microenvironments.
Finally, we speculate that the therapeutic potential of TIM inhibitors that has been demonstrated in animal tumor models does not necessarily translate into clinical therapies for treating human cancer patients because exogenous implantation of established tumor cell lines does not reflect the natural course of immunosurveillance and immunoevasion in tumor microenvironments. Therefore, it is critical to evaluate the clinical implications of immune regulatory drugs such as TIM inhibitors by utilizing genetically modified animal models to evaluate and compare the pro-and anti-tumorigenic actions of host immunity on the temporal and spatial processes of tumorigenesis.
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CONCLUSIONS
We describe the potential role of the TIM gene family in the regulation of anti-and pro-tumorigenic responses during cancer immunosurveillance and evasion. The role of TIM family members in the temporal dynamics of immunosurveillance should be broadly applicable to other molecules that have immune modulatory and antitumor activities. For example, therapeutic strategies for targeting immunosuppressive factors (CTLA-4, PD-1, LAG3, IDO, etc.) or boosting immunostimulatory pathways (CD28, CD137, OX40, etc.) may be promising therapeutic strategies to stimulate antitumor immunity and trigger tumor regression during the early phase of tumor immunosurveillance. In addition, immunomodulation may be useful for treating advanced stage cancer patients in whom tumor-mediated immune regulation does not result in immunoevasion and pro-tumor inflammation. In contrast, targeting immunoregulatory pathways such as TIM, CTLA-4 and PD-1 might be detrimental for controlling tumorigenic activities during the advanced stages of carcinogenesis; restoring innate and antigen-specific immune responses might further amplify protumorigenic inflammation and promote tumor progression.
Recent advances to develop immunoregulatory drugs targeting immune checkpoints such as anti-CTLA-4 mAb and anti-PD-1 mAb elicited potent antitumor responses in patients with advanced solid cancers. 70, 71 Moreover, accumulating evidence has revealed that multiple subsets of immunoregulatory populations, including Treg, MDSC, B7-1 and B7-4-expressing macrophages, contribute to immune suppression and are suitable therapeutic targets in combination with immune checkpoint molecules such as TIM family members. 17 However, it remains largely unknown whether particular immune cell subtypes exist that elicit antitumor responses and promote tumorigenic inflammation by these immune modulatory drugs. Thus, a deep understanding of the spatial and temporal regulatory mechanisms of immunosurveillance and immunoevasion during tumorigenesis should help to correctly regulate the homeostatic and inflammatory balance between host immunity and tumorigenicity in clinical settings.
In conclusion, we discuss the potential impact of TIM family members on tumor initiation and prognosis and their utility as therapeutic targets for treating patients with cancer. The development and elucidation of drugs targeting the TIM gene family should advance our understanding of the balance between beneficial antitumor immunity and harmful immunemediated adverse inflammation and create ideal combinatorial strategies to minimize side effects and maximize clinical responses in the future.
